thymine has been researched along with Neoplasms in 75 studies
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Evaluation demonstrated a trend toward thymidine protection of carboplatin-induced treatment-limiting thrombocytopenia." | 5.09 | Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer. ( Alberti, D; Arzoomanian, RZ; Cohen, JD; Feierabend, C; Jacobson, E; Katschinski, DM; Mehta, M; Olsen, M; Robins, HI; Tiggelaar, CL; Tutsch, K; Wilding, G, 1999) |
| "0%) had at least 1 adverse event leading to study discontinuation." | 2.90 | Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment. ( Bebeau, P; Becerra, C; Rosen, L; Rudek, MA; Saif, MW; Shepard, DR; Sun, W; Winkler, R; Yamashita, F, 2019) |
| " A phase 1 study evaluated relative bioavailability of TAS-102 tablets compared with an oral solution containing equivalent amounts of FTD and TPI." | 2.84 | A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and Tipiracil. ( Becerra, CR; Mizuguchi, H; Patel, M; Von Hoff, D; Yoshida, K, 2017) |
| "Patients with advanced solid tumors (6 M/2 F; median age 58 years; PS 0-1) were enrolled on this study." | 2.82 | Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry. ( Beumer, JH; Chu, E; Croft, M; Faulkner, T; Fawcett, P; Fiejdasz, J; Hague, J; Lee, JJ; Mason, S; Mizuguchi, H; Nugteren, J; Parise, RA; Pollice, L; Seraj, J; Strychor, S; Sun, W; Tedder, C; Yoshida, K, 2016) |
| " Major adverse events were neutropenia, leukopenia, anemia, and nausea." | 2.82 | Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors. ( Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T, 2016) |
| "This study was designed to determine the safety and optimal dosing of TAS-102, a novel oral combination of alphaalphaalpha-trifluorothymidine (FTD) and an inhibitor of thymidine phoshorylase, in patients with solid tumors." | 2.73 | Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. ( Abbruzzese, JL; Fukushima, M; Hoff, PM; Kopetz, S; Kuwata, K; Mita, A; Overman, MJ; Thomas, MB; Varadhachary, G; Wolff, RA; Xiong, H, 2008) |
| "The purpose of the current study was to determine the maximum tolerated dose, dose-limiting toxicities, pharmacokinetic profile, and recommended Phase II dose of oral administration of TAS-102, a novel nucleoside formed by the combination of alpha,alpha,alpha-trifluorothymidine (FTD) and a thymidine phosphorylase inhibitor (TPI: 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione)." | 2.72 | Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. ( Abbruzzese, JL; Bogaard, K; Fukushima, M; Hoff, PM; Hong, DS; Kuwata, K; Lassere, Y; Mita, A, 2006) |
| " This review summarizes the current state of knowledge of FIC with special regard to proposed pathogenetic models (coronary vasospasm, endothelium and cardiomyocytes damage, toxic metabolites, dihydropyrimidine dehydrogenase deficiency); risk and predictive factors; efficacy and usefulness in detection of laboratory markers, electrocardiographic changes and cardiac imaging; and specific treatment, including a novel agent, uridine triacetate." | 2.58 | Fluoropyrimidine-induced cardiotoxicity. ( Aglietta, M; Bonzano, A; Cagnazzo, C; Depetris, I; Filippi, R; Leone, F; Marino, D, 2018) |
| " TAS-102 is an oral combination therapy consisting of trifluridine (FTD), a thymidine-based nucleoside analog, plus tipiracil hydrochloride (TPI), a novel thymidine phosphorylase inhibitor that improves the bioavailability of FTD." | 2.52 | TAS-102, a novel antitumor agent: a review of the mechanism of action. ( Lenz, HJ; Loupakis, F; Stintzing, S, 2015) |
| "Thymineless death is an important cytotoxic response to several classes of antimetabolite agents used in the treatment of patients with carcinomas and hematopoeitic malignancies." | 2.39 | Cellular responses to antimetabolite anticancer agents: cytostasis versus cytotoxicity. ( Houghton, JA; Houghton, PJ, 1996) |
| " Associations of serious fluoropyrimidine adverse effects have focused on inherited deficiency of the catabolic enzyme, dihydropyrimidine dehydrogenase." | 1.48 | Preliminary Evidence for Enhanced Thymine Absorption: A Putative New Phenotype Associated With Fluoropyrimidine Toxicity in Cancer Patients. ( Charles, BG; Cowley, D; Duley, JA; George, R; Harris, M; Helsby, N; Ni, M; Norris, RL; Shannon, C; Sheffield, L; van Kuilenburg, ABP, 2018) |
| "Numerous cancer types exhibit high inter- and intratumor heterogeneity of H1." | 1.43 | The linker histone H1.0 generates epigenetic and functional intratumor heterogeneity. ( Ben-Hamo, R; Biran, A; Burney, MJ; Chakravarty, P; Cohen, AS; Efroni, S; Henser-Brownhill, T; Li, Y; Matthews, N; Meshorer, E; Misteli, T; Nye, E; Patel, H; Scaffidi, P; Spencer-Dene, B; Torres, CM, 2016) |
| "The efficacy of cancer drugs such as cisplatin (Cp) and oxaliplatin (Ox), which covalently bind to DNA to form drug-DNA adducts, is linked to their recognition by repair proteins such as HMGB1a." | 1.38 | Sequence-specific recognition of cancer drug-DNA adducts by HMGB1a repair protein. ( Elder, RM; Jayaraman, A, 2012) |
| "In non-small cell lung cancers, high TK-1 expression was demonstrated in squamous cell carcinomas, but not in adenocarcinomas." | 1.36 | Immunohistochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase, in various types of cancer. ( Kamoshida, S; Kuroda, M; Shintani, M; Takakuwa, Y; Urano, M, 2010) |
| "Relative risks (RRs) of cancer and 95% confidence intervals (CIs) were calculated by Cox proportional hazards regression analysis." | 1.32 | Integrin beta3 Leu33Pro homozygosity and risk of cancer. ( Bojesen, SE; Nordestgaard, BG; Tybjaerg-Hansen, A, 2003) |
| "In many cancers, the most frequent class of mutations is C to T changes within CG dinucleotides of the tumor suppressor gene p53." | 1.29 | A cytosine methyltransferase converts 5-methylcytosine in DNA to thymine. ( Bhagwat, AS; Yebra, MJ, 1995) |
| "All patients had a family history of tumors previously associated with A-T heterozygosity or homozygosity." | 1.29 | ATM mutations in cancer families. ( Croce, CM; Hammarström, L; Lindblom, A; Luo, L; Negrini, M; Vorechovský, I; Webster, AD, 1996) |
| "Uric acid was used as an indicator for tissue-breakdown." | 1.27 | beta-Aminoisobutyric acid as a marker of thymine catabolism in malignancy. ( Abeling, NG; van Bree-Blom, EJ; van Erven, AJ; van Gennip, AH; Voûte, PA, 1987) |
| "Thymine was the major metabolite of TdR." | 1.26 | Clinical pharmacologic effects of thymidine plus 5-FU. ( Holland, JF; Mandel, E; Martin, DS; Ohnuma, T; Roboz, J; Waxman, S, 1980) |
| " Only the pharmacokinetic aspects of these studies are reported in this paper." | 1.26 | Pharmacokinetic studies during phase I trials of high-dose thymidine infusions. ( Bolten, BJ; Chiuten, D; Wiernik, PH; Zaharko, DS, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 38 (50.67) | 18.7374 |
| 1990's | 9 (12.00) | 18.2507 |
| 2000's | 6 (8.00) | 29.6817 |
| 2010's | 19 (25.33) | 24.3611 |
| 2020's | 3 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, Q | 1 |
| Yang, W | 1 |
| Peng, Z | 1 |
| Wang, G | 1 |
| Abou El-Nour, KM | 1 |
| El-Sherbiny, IM | 1 |
| Khairy, GM | 1 |
| Abbas, AM | 1 |
| Salem, EH | 1 |
| Dong, W | 1 |
| Xu, L | 1 |
| Chang, C | 1 |
| Jiang, T | 1 |
| Chen, CP | 1 |
| Zhang, G | 1 |
| Do, H | 1 |
| Molania, R | 1 |
| Mitchell, PL | 1 |
| Vaiskunaite, R | 1 |
| Murdoch, JD | 1 |
| Dobrovic, A | 1 |
| Depetris, I | 1 |
| Marino, D | 1 |
| Bonzano, A | 1 |
| Cagnazzo, C | 1 |
| Filippi, R | 1 |
| Aglietta, M | 1 |
| Leone, F | 1 |
| Duley, JA | 1 |
| Ni, M | 1 |
| Shannon, C | 1 |
| Norris, RL | 1 |
| Sheffield, L | 1 |
| Cowley, D | 1 |
| Harris, M | 1 |
| van Kuilenburg, ABP | 1 |
| Helsby, N | 1 |
| George, R | 1 |
| Charles, BG | 1 |
| Jacobs, BAW | 1 |
| Pluim, D | 1 |
| van der Laan, P | 1 |
| Tzani, A | 1 |
| Beijnen, JH | 1 |
| Schellens, JHM | 1 |
| Saif, MW | 1 |
| Rosen, L | 1 |
| Rudek, MA | 1 |
| Sun, W | 2 |
| Shepard, DR | 1 |
| Becerra, C | 1 |
| Yamashita, F | 1 |
| Bebeau, P | 1 |
| Winkler, R | 1 |
| Milano, G | 1 |
| Lenz, HJ | 1 |
| Stintzing, S | 1 |
| Loupakis, F | 1 |
| Uboha, N | 1 |
| Hochster, HS | 1 |
| Lee, JJ | 1 |
| Seraj, J | 2 |
| Yoshida, K | 3 |
| Mizuguchi, H | 2 |
| Strychor, S | 1 |
| Fiejdasz, J | 1 |
| Faulkner, T | 1 |
| Parise, RA | 1 |
| Fawcett, P | 1 |
| Pollice, L | 1 |
| Mason, S | 1 |
| Hague, J | 1 |
| Croft, M | 1 |
| Nugteren, J | 1 |
| Tedder, C | 1 |
| Chu, E | 1 |
| Beumer, JH | 1 |
| Liu, FT | 1 |
| Zhu, PQ | 1 |
| Ou, YX | 1 |
| Liu, WW | 1 |
| Xia, GF | 1 |
| Luo, HL | 1 |
| Yoshino, T | 2 |
| Kojima, T | 1 |
| Bando, H | 1 |
| Yamazaki, T | 1 |
| Naito, Y | 1 |
| Mukai, H | 1 |
| Fuse, N | 1 |
| Goto, K | 1 |
| Ito, Y | 1 |
| Doi, T | 2 |
| Ohtsu, A | 2 |
| Bendell, JC | 1 |
| Patel, MR | 1 |
| Weaver, R | 1 |
| Lemech, C | 1 |
| Todaro, TG | 1 |
| Pant, S | 1 |
| Arkenau, HT | 1 |
| Torres, CM | 1 |
| Biran, A | 1 |
| Burney, MJ | 1 |
| Patel, H | 1 |
| Henser-Brownhill, T | 1 |
| Cohen, AS | 1 |
| Li, Y | 1 |
| Ben-Hamo, R | 1 |
| Nye, E | 1 |
| Spencer-Dene, B | 1 |
| Chakravarty, P | 1 |
| Efroni, S | 1 |
| Matthews, N | 1 |
| Misteli, T | 1 |
| Meshorer, E | 1 |
| Scaffidi, P | 1 |
| Becerra, CR | 1 |
| Patel, M | 1 |
| Von Hoff, D | 1 |
| Overman, MJ | 2 |
| Varadhachary, G | 2 |
| Kopetz, S | 2 |
| Thomas, MB | 1 |
| Fukushima, M | 3 |
| Kuwata, K | 3 |
| Mita, A | 3 |
| Wolff, RA | 2 |
| Hoff, PM | 2 |
| Xiong, H | 2 |
| Abbruzzese, JL | 3 |
| Hoff, P | 1 |
| Shintani, M | 1 |
| Urano, M | 1 |
| Takakuwa, Y | 1 |
| Kuroda, M | 1 |
| Kamoshida, S | 1 |
| Riahi, S | 1 |
| Eynollahi, S | 1 |
| Ganjali, MR | 1 |
| Mikulski, D | 1 |
| Szeląg, M | 1 |
| Molski, M | 1 |
| Elder, RM | 1 |
| Jayaraman, A | 1 |
| Boku, N | 1 |
| Onozawa, Y | 1 |
| Fukutomi, A | 1 |
| Hironaka, S | 1 |
| Koizumi, W | 1 |
| Sasaki, T | 1 |
| Bojesen, SE | 1 |
| Tybjaerg-Hansen, A | 1 |
| Nordestgaard, BG | 1 |
| PRUSOFF, WH | 1 |
| LAJTHA, LG | 1 |
| WELCH, AD | 1 |
| KIT, S | 3 |
| ROGERS, S | 1 |
| AWAPARA, J | 1 |
| SHULLENBERGER, CC | 1 |
| BECK, C | 2 |
| GRAHAM, OL | 2 |
| GROSS, A | 2 |
| DI MARCO, A | 1 |
| BARBIERI, P | 1 |
| FUOCO, L | 1 |
| RUSCONI, A | 1 |
| ELLISON, RR | 1 |
| TAN, CT | 1 |
| MURPHY, ML | 1 |
| KRAKOFF, IH | 1 |
| BIRNIE, GD | 1 |
| HEIDELBERGER, C | 2 |
| GREKH, IF | 1 |
| KARLINSKAIA, RS | 1 |
| TURBINA, IL | 1 |
| CAMBRIA, A | 1 |
| LOMBARDO, N | 1 |
| GIUFFRIDA, AM | 1 |
| RABOTTI, G | 1 |
| MANOILOV, SE | 1 |
| KITAVIN, GS | 1 |
| COMAR, VE | 1 |
| ORLOVA, EU | 1 |
| UJHAZY, V | 1 |
| WINKLER, A | 1 |
| MORSE, PA | 1 |
| POTTER, VR | 1 |
| JACQUEZ, JA | 1 |
| WOODHOUSE, DL | 1 |
| Shinohara, K | 1 |
| Bando, T | 1 |
| Sasaki, S | 1 |
| Sakakibara, Y | 1 |
| Minoshima, M | 1 |
| Sugiyama, H | 1 |
| Hong, DS | 1 |
| Bogaard, K | 1 |
| Lassere, Y | 1 |
| Ames, BN | 1 |
| van Gennip, AH | 2 |
| Kamerling, JP | 1 |
| de Bree, PK | 1 |
| Wadman, SK | 1 |
| Ohnuma, T | 1 |
| Roboz, J | 1 |
| Waxman, S | 1 |
| Mandel, E | 1 |
| Martin, DS | 1 |
| Holland, JF | 1 |
| Yebra, MJ | 1 |
| Bhagwat, AS | 1 |
| Cao, EH | 1 |
| Wang, JJ | 1 |
| Vorechovský, I | 1 |
| Luo, L | 1 |
| Lindblom, A | 1 |
| Negrini, M | 1 |
| Webster, AD | 1 |
| Croce, CM | 1 |
| Hammarström, L | 1 |
| Denissenko, MF | 1 |
| Pao, A | 1 |
| Pfeifer, GP | 1 |
| Tang, M | 1 |
| Houghton, JA | 1 |
| Houghton, PJ | 1 |
| Robins, HI | 1 |
| Tutsch, K | 1 |
| Katschinski, DM | 1 |
| Jacobson, E | 1 |
| Mehta, M | 1 |
| Olsen, M | 1 |
| Cohen, JD | 1 |
| Tiggelaar, CL | 1 |
| Arzoomanian, RZ | 1 |
| Alberti, D | 1 |
| Feierabend, C | 1 |
| Wilding, G | 1 |
| Klecker, RW | 2 |
| Collins, JM | 2 |
| Müller, WE | 1 |
| Zahn, RK | 1 |
| Zaharko, DS | 2 |
| Bolten, BJ | 2 |
| Kobayashi, T | 1 |
| Blasberg, RG | 1 |
| Lee, SS | 1 |
| Giovanella, BC | 1 |
| Stehlin, JS | 1 |
| Chiuten, D | 1 |
| Wiernik, PH | 1 |
| Pauly, JL | 1 |
| Schuller, MG | 1 |
| Zelcer, AA | 1 |
| Kirss, TA | 1 |
| Gore, SS | 1 |
| Germain, MJ | 1 |
| Singer, B | 1 |
| Essigmann, JM | 1 |
| Wani, AA | 1 |
| Wani, G | 1 |
| D'Ambrosio, SM | 1 |
| Dreizen, S | 1 |
| McCredie, KB | 1 |
| Keating, MJ | 1 |
| Andersson, BS | 1 |
| Tuchman, M | 1 |
| Roemeling, RV | 1 |
| Hrushesky, WA | 1 |
| Sothern, RB | 1 |
| O'Dea, RF | 1 |
| van Bree-Blom, EJ | 1 |
| Abeling, NG | 1 |
| van Erven, AJ | 1 |
| Voûte, PA | 1 |
| Schilsky, RL | 1 |
| O'Laughlin, K | 1 |
| Ratain, MJ | 1 |
| Jenkins, JF | 1 |
| Kinsella, TJ | 1 |
| Fine, RL | 1 |
| Strong, JM | 1 |
| Wolberg, WH | 2 |
| Nielsen, HR | 1 |
| Nyholm, K | 1 |
| Sjolin, KE | 1 |
| Barnes, EW | 1 |
| Irvine, WJ | 1 |
| Friedkin, M | 2 |
| Inoue, M | 1 |
| Nagata, Y | 1 |
| Hitchings, GH | 1 |
| Groth, DP | 1 |
| D'Angelo, JM | 1 |
| Vogler, WR | 1 |
| Mingioli, ES | 1 |
| Betz, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1 Study to Evaluate the Cardiac Safety of Orally Administered TAS-102 in Patients With Advanced Solid Tumors[NCT01867879] | Phase 1 | 44 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for thymine and Neoplasms
| Article | Year |
|---|---|
Recent advances in the synthetic thymidine phosphorylase inhibitors for cancer therapy.
Topics: Antineoplastic Agents; Enzyme Inhibitors; Humans; Molecular Docking Simulation; Neoplasms; Phosphate | 2022 |
Fluoropyrimidine-induced cardiotoxicity.
Topics: Acetates; Capecitabine; Cardiotoxicity; Cardiovascular Diseases; Drug Combinations; Fluorouracil; Hu | 2018 |
TAS-102, a novel antitumor agent: a review of the mechanism of action.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Combinations | 2015 |
TAS-102: a novel antimetabolite for the 21st century.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2016 |
Positive association between IL-16 rs1131445 polymorphism and cancer risk: a meta-analysis.
Topics: Alleles; Asian People; Biomarkers, Tumor; Cytosine; Databases, Factual; Evidence-Based Medicine; Gen | 2016 |
The detection of environmental mutagens and potential carcinogens.
Topics: Aging; Animals; Biological Assay; Biotransformation; Carcinogens, Environmental; DNA; DNA Repair; Fe | 1984 |
Cellular responses to antimetabolite anticancer agents: cytostasis versus cytotoxicity.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Death; Cell Division; Deoxyribonucleotides; Enzyme In | 1996 |
Bleomycin, an antibiotic that removes thymine from double-stranded DNA.
Topics: Antiviral Agents; Base Sequence; Bleomycin; Cell Division; Chemical Phenomena; Chemistry; Chromatin; | 1977 |
Site-specific mutagenesis: retrospective and prospective.
Topics: Animals; DNA; DNA Damage; Guanine; Humans; Mutagenesis; Neoplasms; Thymine | 1991 |
Repair of O4-alkylthymine damage in human cells.
Topics: Alkylating Agents; Alkylation; Cell Transformation, Neoplastic; DNA; DNA Damage; DNA Repair; Humans; | 1990 |
Clinical syndromes associated with thymic disorders.
Topics: Agammaglobulinemia; Animals; Autoimmune Diseases; Erythroplasia; Humans; Hyperthyroidism; Immunologi | 1973 |
Thymidylate synthetase.
Topics: Animals; Binding Sites; Deoxyuridine; Drug Stability; Escherichia coli; Fluorouracil; Folic Acid Def | 1973 |
Chemical carcinogenesis, chemotherapy: cancer's continuing core challenges--G. H. A. Clowes Memorial Lecture.
Topics: Animals; Antineoplastic Agents; Arginase; Benz(a)Anthracenes; Benzopyrenes; Carcinogens; Cell Divisi | 1970 |
[Regulation of DNA biosynthesis and cell division].
Topics: Arginine; Carbon Isotopes; Cell Division; Cell Membrane; DNA; DNA, Bacterial; Electrophoresis; Esche | 1971 |
Chemotherapy and comparative biochemistry: G. H. A. Clowes memorial lecture.
Topics: Allopurinol; Animals; Antimetabolites; Azathioprine; Binding Sites; Drug Therapy; Enzyme Inhibitors; | 1969 |
10 trials available for thymine and Neoplasms
| Article | Year |
|---|---|
Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Bilirubin; Drug Administration Schedule; D | 2019 |
Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry.
Topics: Aged; Antineoplastic Agents; Chromatography, Liquid; Drug Combinations; Female; Humans; Male; Middle | 2016 |
Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Topics: Aged; Anemia; Antineoplastic Agents; Area Under Curve; Asian People; Biological Availability; Cross- | 2016 |
Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Drug Administr | 2016 |
A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and Tipiracil.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Biological Availability; Cross-Over Studies; Drug | 2017 |
Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Sch | 2008 |
Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neopl | 2008 |
Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Do | 2012 |
Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Asthenia; Dose-Response | 2006 |
Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Cohort Studies; Drug Administration Schedule; Drug | 1999 |
50 other studies available for thymine and Neoplasms
| Article | Year |
|---|---|
Investigation of thymine as a potential cancer biomarker employing tryptophan with nanomaterials as a biosensor.
Topics: Biosensing Techniques; Gold; Graphite; Humans; Metal Nanoparticles; Neoplasms; Thymine; Tryptophan | 2023 |
A novel self-assembled nucleobase-nanofiber platform of CDN to activate the STING pathway for synergistic cancer immunotherapy.
Topics: Animals; Arginine; Immunotherapy; Mice; Nanofibers; Neoplasms; Thymine | 2023 |
Reducing Artifactual
Topics: Cell Line, Tumor; Diagnostic Errors; DNA Glycosylases; False Positive Reactions; Genes, erbB-1; Huma | 2017 |
Preliminary Evidence for Enhanced Thymine Absorption: A Putative New Phenotype Associated With Fluoropyrimidine Toxicity in Cancer Patients.
Topics: Adult; Aged; Amidohydrolases; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil | 2018 |
Development and validation of a quantitative method for thymidine phosphorylase activity in peripheral blood mononuclear cells.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromatography, High Pressure Liquid; Humans; Leukocy | 2018 |
Fluoropyrimidines and DPD testing: is there truly an inexorable link?
Topics: Antineoplastic Agents; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP | 2019 |
The linker histone H1.0 generates epigenetic and functional intratumor heterogeneity.
Topics: Adenine; Cell Line, Tumor; DNA; DNA Methylation; Enhancer Elements, Genetic; Epigenesis, Genetic; Ge | 2016 |
Immunohistochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase, in various types of cancer.
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Drug Resistance, Neoplasm; Humans; Immunohistoch | 2010 |
Computational studies on effects of MDMA as an anticancer drug on DNA.
Topics: Adenine; Antineoplastic Agents; Base Pairing; Cytosine; DNA; Drug Design; Guanine; Humans; Intercala | 2010 |
Quantum-chemical study of interactions of trans-resveratrol with guanine-thymine dinucleotide and DNA-nucleobases.
Topics: Adenine; Antineoplastic Agents, Phytogenic; Cytosine; DNA; DNA Breaks; Guanine; Humans; Hydrogen Bon | 2011 |
Sequence-specific recognition of cancer drug-DNA adducts by HMGB1a repair protein.
Topics: Antineoplastic Agents; Base Sequence; Cisplatin; Computer Simulation; DNA Adducts; DNA Repair; DNA, | 2012 |
Integrin beta3 Leu33Pro homozygosity and risk of cancer.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Animals; Cytosine; Denmark; Disease Progression; Female; Ge | 2003 |
Effect of the deoxyriboside of 6-azathymine (azathymidine) on the biosynthesis of deoxyribonucleic acid by bone marrow and neoplastic cells (in vitro).
Topics: Bone Marrow; DNA; In Vitro Techniques; Neoplasms; Nucleic Acids; Thymine | 1956 |
The mechanism of deoxyribonucleic acid-thymine biosynthesis by lymphatic tissues and tumors.
Topics: DNA; DNA Replication; Lymphoid Tissue; Neoplasms; Thymine | 1957 |
Studies of the mechanism of action of urethane in initiating pulmonary adenomas in mice. II. Its relation to nucleic acid synthesis.
Topics: Adenine; Adenoma; Animals; DNA; Lung Neoplasms; Mice; Neoplasms; Nucleic Acids; Orotic Acid; Pyrimid | 1957 |
Urinary excretion of beta-aminoisobutyric acid after administration of thymine and nitrogen mustard.
Topics: Amino Acids; Aminoisobutyric Acids; Body Fluids; Humans; Mechlorethamine; Neoplasms; Nitrogen Mustar | 1957 |
Effect of 5-bromodeoxyuridine on deoxyribonucleic acid-thymine synthesis and cell metabolism of lymphatic tissues and tumors.
Topics: Bromodeoxyuridine; DNA; DNA Replication; Lymphatic System; Lymphoid Tissue; Neoplasms; Nucleosides; | 1958 |
Further studies on the pathways of synthesis of thymine compounds by lymphatic tissues and tumors.
Topics: Encephalomyelitis; Lymphoid Tissue; Neoplasms; Thymine | 1958 |
Utilization of thymine and thymidine in DNA synthesis of Ehrlich and Yoshida ascites tumor cells incubated "in vitro".
Topics: Animals; Ascites; DNA; DNA Replication; In Vitro Techniques; Neoplasms; Nucleosides; Nucleotides; Sa | 1960 |
[Clinical investigations of 6-azathymine: a thymine analog].
Topics: Leukemia; Neoplasms; Organic Chemicals; Thymine | 1960 |
In vitro synthesis of acidsoluble thymine compounds by human neoplastic tissues.
Topics: DNA; DNA, Neoplasm; Floxuridine; Fluorouracil; Humans; In Vitro Techniques; Neoplasms; Thymine | 1963 |
[ON THE EFFECT OF CERTAIN PYRIMIDINE DERIVATIVES ON THE METASTASIZATION OF TRANSPLANTABLE SSK RAT SARCOMA].
Topics: Cytosine; Neoplasm Metastasis; Neoplasms; Pharmacology; Pyrimidines; Rats; Research; Sarcoma; Sarcom | 1964 |
[INCORPORATION OF FORMATE-C14 IN THE BASES OF THE NUCLEIC ACIDS OF STICKER'S TUMOR IN VIVO AND IN VITRO].
Topics: Adenine; Aspartic Acid; Carbon Isotopes; DNA; DNA, Neoplasm; Dogs; Formates; Glucose; Glutamine; In | 1963 |
SPECIFICITY OF DNA FROM NEOPLASTIC TISSUES IN VIVO AND IN VITRO.
Topics: Adenine; Animals; Carbon Isotopes; Cytosine; DNA; DNA, Neoplasm; Formates; Guanine; Histocytochemist | 1964 |
ON THE OXIDATIVE PHOSPHORYLATION AND NUCLEIC ACIDS METABOLISM IN SOME ORGANS OF ANIMALS WITH TRANSPLANTABLE TUMOURS.
Topics: Adenine; Carbohydrate Metabolism; Cytosine; DNA; DNA, Neoplasm; Glycolysis; Guanine; Intestines; Kid | 1964 |
NITROGEN MUSTARD-RESISTANT YOSHIDA SARCOMA AND CROSS-RESISTANCE STUDIES.
Topics: Animals; Cyclophosphamide; Mannitol; Mannomustine; Mechlorethamine; Neoplasm Transplantation; Neopla | 1965 |
PYRIMIDINE METABOLISM IN TISSUE CULTURE CELLS DERIVED FROM RAT HEPATOMAS. I. SUSPENSION CELL CULTURES DERIVED FROM THE NOVIKOFF HEPATOMA.
Topics: Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Floxuridine; Fluorouracil; Glycine; Liv | 1965 |
Permeability of Ehrlich cells to uracil, thymine and fluorouracil.
Topics: Fluorouracil; Humans; Neoplasms; Permeability; Thymine; Uracil | 1962 |
The composition of nucleic acids; the guanine and thymine content of nucleic acids isolated from normal tissues and animal tumours.
Topics: Guanine; Neoplasms; Nucleic Acids; Thymine | 1949 |
Antitumor activity of sequence-specific alkylating agents: pyrolle-imidazole CBI conjugates with indole linker.
Topics: Adenine; Alkylation; Animals; Antineoplastic Agents, Alkylating; Base Sequence; Cell Line, Tumor; Cy | 2006 |
Linear relationship between the R- and S-enantiomers of a beta-aminoisobutyric acid in human urine.
Topics: Adolescent; Aminoisobutyric Acids; Child; Child, Preschool; Humans; Infant; Leukemia, Lymphoid; Mode | 1981 |
Clinical pharmacologic effects of thymidine plus 5-FU.
Topics: Adult; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouraci | 1980 |
A cytosine methyltransferase converts 5-methylcytosine in DNA to thymine.
Topics: 5-Methylcytosine; Cytosine; DNA; DNA-Cytosine Methylases; Escherichia coli; Humans; Methylation; Mol | 1995 |
Oxidative damage to DNA: levels of thymine glycol and thymidine glycol in neoplastic human urines.
Topics: Adolescent; Adult; Aged; DNA Damage; DNA Repair; Female; Humans; Male; Middle Aged; Neoplasms; Oxida | 1993 |
ATM mutations in cancer families.
Topics: Adenine; Alleles; Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; C | 1996 |
Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers.
Topics: 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide; Base Sequence; Cells, Cultured; Codon; DNA Adduc | 1998 |
Thymidine phosphorylase as a target for imaging and therapy with thymine analogs.
Topics: DNA; Humans; Neoplasms; Neovascularization, Pathologic; Nucleosides; Prodrugs; Thymidine Phosphoryla | 2001 |
Thymidine and thymine in biologic fluids during high-dose infusions of thymidine in mice, monkeys, and man.
Topics: Animals; Body Fluids; Haplorhini; Humans; Infusions, Parenteral; Kidney; Metabolic Clearance Rate; M | 1979 |
Pharmacokinetic studies during phase I trials of high-dose thymidine infusions.
Topics: Drug Evaluation; Female; Humans; Infusions, Parenteral; Kidney; Male; Metabolic Clearance Rate; Neop | 1979 |
Identification and comparative analysis of thymidine phosphorylase in the plasma of healthy subjects and cancer patients.
Topics: Humans; In Vitro Techniques; Neoplasms; Pentosyltransferases; Thymidine; Thymidine Phosphorylase; Th | 1977 |
Nutritional deficiencies in patients receiving cancer chemotherapy.
Topics: Antineoplastic Agents; Cachexia; Folic Acid Deficiency; Humans; Hypoproteinemia; Methotrexate; Neopl | 1990 |
Dihydropyrimidine dehydrogenase activity in human blood mononuclear cells.
Topics: Adult; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Dihydrouracil Dehydrogenase (NADP | 1989 |
beta-Aminoisobutyric acid as a marker of thymine catabolism in malignancy.
Topics: Adolescent; Aminobutyrates; Child; Child, Preschool; Humans; Infant; Leukocyte Count; Neoplasms; Pur | 1987 |
Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain; Cisplatin; Digestiv | 1986 |
Clinical pharmacology of 5-iodo-2'-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation.
Topics: Chromatography, High Pressure Liquid; Deoxyuridine; Humans; Idoxuridine; Infusions, Parenteral; Neop | 1985 |
Biochemical approaches to prediction of response in solid tumors.
Topics: Adenocarcinoma; Antineoplastic Agents; Carbon Isotopes; Carcinoma, Hepatocellular; Carcinoma, Squamo | 1971 |
Relationship between urinary beta-aminoisobutyric acid and transfer RNA turnover in cancer patients.
Topics: Aged; Aminoisobutyric Acids; Carcinoma, Transitional Cell; Colonic Neoplasms; DNA, Neoplasm; Female; | 1974 |
The biochemist's outlook on cancer research.
Topics: Aerobiosis; Animals; Antineoplastic Agents; Biochemistry; Carbon Radioisotopes; Cell Transformation, | 1973 |
Selective metabolic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea upon de novo purine biosynthesis.
Topics: Acute Disease; Amino Acids; Animals; Antineoplastic Agents; Ascitic Fluid; Carbon Isotopes; Carcinom | 1971 |
The effect of 5-fluorouracil on DNA-thymine synthesis in human tumors.
Topics: Carbon Isotopes; DNA, Neoplasm; Fluorouracil; Formates; Humans; Neoplasms; Thymidine; Thymine; Triti | 1969 |